{"id":"W4410424571","doi":"10.1016/j.esmoop.2025.105051","title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Genentech; Ipsen; Servier; Astellas Pharma; Eisai; Daiichi-Sankyo; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Medicine; Antibody; Programmed cell death 1; Monoclonal; Cancer research; PD-L1; Oncology; Immunology; Immunotherapy; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386842,0.0002890551,0.0007987818,0.0004322773,0.0001019672,0.00007550832,0.0002670842,0.0000954549,0.00001916681],"category_scores_gemma":[0.00001722039,0.0002304203,0.00002840801,0.0008509355,0.0001542615,0.0004480659,0.0001272499,0.0001902446,4.146398e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001219756,"about_ca_system_score_gemma":0.0001347378,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.009448296,"about_ca_topic_score_gemma":0.02697896,"domain_scores_codex":[0.9980713,0.00009864115,0.0005759995,0.0005505134,0.0003431275,0.0003604362],"domain_scores_gemma":[0.9991683,0.0000384305,0.0002029237,0.0004075558,0.0001177219,0.00006506294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007188028,0.00431794,0.9836506,0.0001444964,0.0001428632,0.00008372658,0.001409545,0.00006960652,0.0009510135,0.00005807514,0.000009519544,0.001974565],"study_design_scores_gemma":[0.04642598,0.00391216,0.943867,0.001256149,0.0000638832,0.00000468395,0.001249671,0.00008087129,0.002768993,0.00003230403,0.00008205665,0.0002562451],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958262,0.0001418251,0.00001109535,0.0002045626,0.00005690172,0.003481019,0.00001227111,0.00001922348,0.0002468834],"genre_scores_gemma":[0.9991521,0.00007414393,0.0002893469,0.00007934782,0.00000563699,0.0001302785,0.0001660657,0.00002885248,0.00007420003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03978362,"threshold_uncertainty_score":0.9971479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01480101674882538,"score_gpt":0.3076671963837465,"score_spread":0.2928661796349211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}